Acute parvovirus B19-associated inflammatory musculoskeletal disease: clinical phenotypes and remission trajectories from the GIRRCS Network
Clicks: 1
ID: 325830
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #194 of 197 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 197 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVE: To describe clinical phenotype, selected imaging findings and remission trajectories in adults with acute parvovirus B19-associated inflammatory musculoskeletal disease referred for rheumatological assessment. METHODS: This was a non-interventional multicentre observational study in GIRRCS rheumatology units. Adults with new-onset inflammatory musculoskeletal manifestations, positive anti-parvovirus B19 IgM and symptom onset within 4 weeks were enrolled. Clinical, laboratory and clinically indicated imaging data were collected. Time to first documented clinical remission was defined as the interval from symptom onset to the first rheumatologist-confirmed assessment showing resolution of inflammatory musculoskeletal manifestations. Patients requiring disease-modifying escalation were analysed separately. RESULTS: Twenty-four adults were enrolled; 18 were women (75.0%) and mean age was 44.4±14.8 years. Clinical involvement was polyarticular in 14 patients (58.3%) and oligoarticular in 10 (41.7%); enthesitis occurred in 4 (16.7%) and dactylitis was absent. Inflammatory markers were modestly elevated, and most patients with complete autoantibody data were seronegative. Imaging was performed selectively and documented inflammatory abnormalities in clinically indicated examinations. Follow-up data were available for 21 patients, of whom 20 (95.2%) achieved clinical remission without DMARD escalation; median documented remission timing was 21 days (IQR 10-60; range 7-135). One patient required biologic escalation for persistent inflammatory disease. Exploratory regression analyses did not identify robust associations with documented remission timing. CONCLUSION: Acute parvovirus B19-associated inflammatory musculoskeletal disease may mimic inflammatory rheumatic disease in adults referred for rheumatological assessment. Most patients achieved remission without disease-modifying escalation, although remission timing varied and one patient required biologic therapy for persistent inflammatory disease.
| Reference Key |
openalex_W7203869416
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Piero Ruscitti, Luisa Costa, Antonella Mastrangelo, Federica Viapiano, Marco Tasso, Giulia Sgarlata, Mario Cascone, Azadeh Shariat Panahi, Federico Perosa, Paola Cipriani, G. Guggino, Roberto Giacomelli, Francesco Caso |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag456
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.